Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash from Financing Activities (2020 - 2025)

Bolt Biotherapeutics' Cash from Financing Activities history spans 6 years, with the latest figure at $14000.0 for Q2 2025.

  • For Q2 2025, Cash from Financing Activities fell 82.28% year-over-year to $14000.0; the TTM value through Sep 2025 reached $43000.0, down 76.76%, while the annual FY2024 figure was $108000.0, 57.31% down from the prior year.
  • Cash from Financing Activities for Q2 2025 was $14000.0 at Bolt Biotherapeutics, down from $29000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $297.0 million in Q1 2021 and bottomed at $14000.0 in Q2 2025.
  • The 5-year median for Cash from Financing Activities is $144000.0 (2022), against an average of $28.3 million.
  • The largest annual shift saw Cash from Financing Activities soared 873485.29% in 2021 before it plummeted 99.96% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $495000.0 in 2021, then tumbled by 70.91% to $144000.0 in 2022, then dropped by 26.39% to $106000.0 in 2023, then crashed by 72.64% to $29000.0 in 2024, then crashed by 51.72% to $14000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Cash from Financing Activities are $14000.0 (Q2 2025), $29000.0 (Q4 2024), and $79000.0 (Q2 2024).